Akèy › Metiyè › Biochemists and Biophysicists › Durham, NC
Biochemists and Biophysicists nan Durham, NC: Salè H-1B
366 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Durham, NC. Salè baz medyàn ofri $68,000; mwatye mitan $61,000–$77,854.
Demann (LCA)366
Salè medyan ofri$68,000
Mwatye salè yo$61,000–$77,854
10yèm–90yèm pousantaj$57,300–$92,900
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $63,807 |
| Nivo II (kalifye) | $75,254 |
| Nivo III (eksperyans) | $116,762 |
| Nivo IV (plen kompetans) | $134,000 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| Duke University | 320 | $65,579 |
| BioAgilytix Labs, LLC | 16 | $117,762 |
| KBI Biopharma, Inc. | 12 | $90,000 |
| Imugene (USA) Inc. | 3 | $134,000 |
| ElevateBio Technologies, Inc. | 3 | $95,000 |
| Novartis Gene Therapies, Inc. | 2 | $96,647 |
| Howard Hughes Medical Institute | 2 | $71,994 |
| Duke University Health System | 2 | $65,869 |
| Precision BioSciences, Inc. | 1 | $130,000 |
| Xilis, Inc. | 1 | $85,000 |
| Biogen Inc. | 1 | $82,326 |
| EpiCypher, Inc. | 1 | $130,957 |
| GreenLight Biosciences, Inc. | 1 | $99,840 |
| Novartis Services Inc. | 1 | $100,048 |
Tit travay
- Postdoctoral Associate109
- Research Associate Senior86
- Research Associate, Sr73
- Research Scientist18
- Research Scholar13
- Scientist I8
- Scientist III5
- Manager I5
- Assistant Professor4
- Specialist - Quality Control3
- Associate in Research3
- Post-Doctoral Associate3
- Scientist II3
- Research Scientist - Senior2
- Pharmacokineticist II2
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).